Screener
Oruka Therapeutics, Inc. ORKA Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Oruka Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001213900-26-055769
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Series B non-voting convertible preferred stock, $0.001 par value; 251,504 shares authorized as of March 31, 2026 and December 31, 2025; 137,138 shares issued and outstanding as of March 31, 2026 and December 31, 2025 | 2,931 | 2,931 |
| Common stock, $0.001 par value; 545,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 50,167,623 and 48,722,309 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 50 | 49 |
| Additional paid-in capital | 705,196 | 657,561 |
| Accumulated other comprehensive income (loss) | (480) | 546 |
| Accumulated deficit | (220,977) | (189,157) |
| Total stockholders’ equity | 486,720 | 471,930 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Oruka Therapeutics, Inc.'s common stock, par value (in dollars per share)?
- Oruka Therapeutics, Inc. (ORKA) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Oruka Therapeutics, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
- Oruka Therapeutics, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
Ask your AI about Oruka Therapeutics, Inc.'s common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude